Press releases
You will be able to find all of our recent press releases. You can search by keyword or filter by year/business category to quickly find what you need.
You may also want to view our USA press releases and Asia press releases.
Press releases for our local operating companies can be viewed on our individual country websites.
Filter by
-
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, mult...
Read more -
GSK and Save the Children call for developing country innovations to enter $1 million award
GSK and Save the Children today launched their fourth annual $1 million Healthcare Innovation Award.
Read more -
Update on GSK’s response to the Zika virus disease outbreak
Since the outbreak of Zika virus disease began in the Americas late last year, GSK has been asses...
Read more -
GSK announces start of phase I oncology study with its ICOS agonist antibody
The start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costi...
Read more -
FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients
FULFIL - Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy
Read more -
Executive Director Change
Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the...
Read more -
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for d...
Read more -
GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with rheumatoid arthritis
The results from the positive SIRROUND-D study are being presented at the Annual European Congres...
Read more -
New Phase III data shows greater treatment response with GSK’s Benlysta® (belimumab) vs placebo in patients with highly active SLE
BLISS-SC builds on an extensive clinical trial programme for belimumab, which is the largest clin...
Read more -
ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
Agreement supports the first ‘Treat All’ programme for HIV in sub-Saharan Africa, where 70% of pe...
Read more -
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
Acceleration of filing of US New Drug Application now expected by end of 2016
Read more -
Board and Committee changes
Dr Vivienne Cox, CBE, has been appointed to the Board of the Company as a Non-Executive Director ...
Read more -
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID
GSK, Fondazione Telethon and Ospedale San Raffaele gain approval to provide life-saving gene ther...
Read more -
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK today announced the publication in BLOOD of the long-term safety and efficacy data from an an...
Read more -
Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) w...
Read more -
GSK presents new data from Breo® Ellipta® SUMMIT study in patients with COPD at ATS Conference
GSK presents new data at the American Thoracic Society Conference from two pre-specified analyses...
Read more -
GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium
GSK and Innoviva, Inc. announce results from data presented at the American Thoracic Society 2016...
Read more -
GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal gr...
Read more -
European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries
Major milestone for the GSK and Save the Children partnership and its mission to help save the li...
Read more -
Results announcement for the first quarter 2016
GSK delivers strong Q1 performance with sales of £6.2 billion (+8% CER), core EPS 19.8p (+8% CER)...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
